Fosamax Plus D Patent Expiration

Fosamax Plus D is a drug owned by Organon Llc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 17, 2019. Details of Fosamax Plus D's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5994329

(Pediatric)

Method for inhibiting bone resorption
Jan, 2019

(5 years ago)

Expired
US5994329 Method for inhibiting bone resorption
Jul, 2018

(6 years ago)

Expired
US6090410

(Pediatric)

Dry mix formulation for bisphosphonic acids
Jun, 2013

(11 years ago)

Expired
US5358941

(Pediatric)

Dry mix formulation for bisphosphonic acids with lactose
Jun, 2013

(11 years ago)

Expired
US5681590

(Pediatric)

Dry mix formulation for bisphosphonic acids
Jun, 2013

(11 years ago)

Expired
US5681590 Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

Expired
US5358941 Dry mix formulation for bisphosphonic acids with lactose
Dec, 2012

(11 years ago)

Expired
US6090410 Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Fosamax Plus D is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fosamax Plus D's family patents as well as insights into ongoing legal events on those patents.

Fosamax Plus D's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Fosamax Plus D's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 17, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Fosamax Plus D Generics:

There are no approved generic versions for Fosamax Plus D as of now.

How can I launch a generic of Fosamax Plus D before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Fosamax Plus D's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Fosamax Plus D's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Fosamax Plus D -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
70 mg/2800 IU and 70 mg/5600 IU 20 Nov, 2007 1 17 Jul, 2018 Extinguished





About Fosamax Plus D

Fosamax Plus D is a drug owned by Organon Llc. It is used for improving bone mass and treating osteoporosis in postmenopausal women and men. Fosamax Plus D uses Alendronate Sodium; Cholecalciferol as an active ingredient. Fosamax Plus D was launched by Organon Llc in 2005.

Approval Date:

Fosamax Plus D was approved by FDA for market use on 07 April, 2005.

Active Ingredient:

Fosamax Plus D uses Alendronate Sodium; Cholecalciferol as the active ingredient. Check out other Drugs and Companies using Alendronate Sodium; Cholecalciferol ingredient

Treatment:

Fosamax Plus D is used for improving bone mass and treating osteoporosis in postmenopausal women and men.

Dosage:

Fosamax Plus D is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 70MG BASE;2,800 IU TABLET Prescription ORAL
EQ 70MG BASE;5,600 IU TABLET Prescription ORAL